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Desymmetrization synthesis strategy has simpliﬁed and improved the efﬁciency of synthesis, which
attracted great attention in the past few decades. Since the strategy has been developed rapidly and
got a wide range of applications in natural product total synthesis, the rules are urgent to be summarized.
In this Letter, the recent developments of desymmetrization protocol in natural product total synthesis
were summarized.
 2014 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
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Symmetry is a nature’s beauty and implied in the structure of a
large number of natural products. The desymmetrization synthesisstrategy can afford the desired product easily from the widely
available symmetry molecular. As shown in Scheme 1, this strategy
has simpliﬁed and improved the efﬁciency of synthesis, which
attracted great attention in the past few decades. Since the strategy
has been developed rapidly1 and got a wide range of applications
in natural product total synthesis, the rules are urgent to be
summarized.
HO OH
S
S
O
1) base, crown ether
2) BnBr(S, S)-2
1
3
4
5a >98% ee
O
n-C12H25
O
O
O
Me
OH
OHOH
6a
O
O
SS
O
O
OO
SS
O
O
OBnO
BnO OH
Mosin B
1
BnO OH
5b
(R, R)-2
6b
O
n-C12H25
O
O
O
Me
OH
OHOH
(a)
(b)
Scheme 2. Desymmetrization of diol 1 by chiral C2-symmetric bis-sulfoxide.
OH OH
O
O
O
H
H
H
10 mol% PdCl2
CuCl, CO
NaOAc, HOAc
11 12
O
O
H
H
H
Et
H H
H
Br
Br
(-)-Kumausallene 10
Scheme 4. Desymmetrization of C2-symmetric diol 11.
"conditions"
Easier
Starting
Materials
steps
Natural
Products
More efficient
Scheme 1. Overview of desymmetrization strategies for total synthesis.
7148 M. Wang et al. / Tetrahedron Letters 55 (2014) 7147–7155Here, we summarize the strategy of desymmetrization for nat-
ural product total synthesis during the past ﬁfteen years. This
review addressed the desymmetrization methods for various sym-
metry functional groups (including diol, carboxylic ester, a-car-
bonyl, amine and ether), unsaturated CAC bond, and C2
symmetric molecular structures in total synthesis. Most of the ele-
gant desymmetrization methods could shorten the synthesis
routes dramatically.
The desymmetrization of symmetry functional group
Diol
The desymmetrization of diols is a most common desymmetri-
zation strategy in total synthesis which includes chemical catalysis
and enzymatic catalysis.Bullatacin 9
O
OH
O
OHHO
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OEt
OEt
OEt
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7
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Scheme 3. Desymmetrization of diol 7 by triethyl orthoacetate.Chemical catalysis
Mosin B was isolated by McLaughlin and co-workers from the
bark of Annona squamosa in 1997. As a mono-tetrahydrofuran
acetogenin, it has selective and potent cytotoxic activity against
the human pancreatic tumor cell line.2a
In 2001, Tanaka group2b reported the ﬁrst total synthesis of
Mosin B 6a in 20 steps from desymmetrized alcohol 5a and overall
yield was 1.1%. This work was accomplished by using asymmetric
desymmetrization of the r-symmetric diol 1 as one of key steps.
They used C2-symmetric bis-sulfoxide (S,S)-2 as a chiral auxiliary,
which developed by themselves2b, and acetalization of meso-diol
1 gave product 3. Base-promoted diastereoselective acetal ﬁssion
of 3 followed by O-benzyl protected of the resulting alkoxide to
prevent recyclization afforded 4. After removing the chiral auxil-
iary, 5a can be obtained in 98% ee (Scheme 2a). The unnatural dia-
stereomer 6b also can be synthesized from 5b using (R,R)-2 as a
chiral auxiliary by the same procedure (Scheme 2b). They sug-
gested that natural mosin B is 6a, not 6b by these synthetic results.
Antiproliferative effects of 6a and 6b were also investigated in
their subsequent work.2c
In 2006, Pagenkopf group reported the total synthesis of Bullat-
acin 9 that was isolated from the tropical plant family Annonaceae.3
The desymmetrization of 7was accomplished by using triethyl ort-
hoacetate as the acetylation reagent to give monoacetate 8. 8 is a
critical intermediate for the synthesis of bis(THF) core segment
(Scheme 3).
()-Kumausallene 10, is one member of the nonisoprenoid ses-
quiterpenes family and was isolated from the marine red alga Lau-
rencia by Kurosawa group in 1983.4 Tang and co-workers
developed enantioselective total synthesis of ()-Kumausallene
10 through a desymmetrization strategy for the construction of
the 2,5-cis-substituted THF ring.5 Their synthesis began with the
readily prepared C2-symmetric diol 11 (96% ee). The palladium-
catalyzed cascade reaction of 11 provided bicyclic lactone 12 in
good yield as a single stereoisomer. Having the bicyclic lactone
12 in hand, they accomplished the assembly of ()-Kumausallene
10 in eight steps from 12 (Scheme 4).
As a macrolide natural product, Peloruside A was isolated from
a marine sponge Mycale hentscheli, which shows antimitoticOH
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18-epi-Peloruside A 15 using an alkyne linchpin strategy.7 In their
synthetic route, the desymmetrization of meso-1,3-diol 13 was
completed by using a dinuclear zinc asymmetric catalyst previ-
ously developed in their laboratory.8 Enantioenriched mono-
benzoylated product 14 (86% ee) can be obtained when using
catalytic diethylzinc and (S,S)-ProPhenol (Scheme 5).O
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Scheme 9. Desymmetrization of diol 28a, b for the total synthesis of Murisolin.()-Kaitocephalin 16 was isolated from the ﬁlamentous fungus
Eupenicillium shearii PF1191 by Shin-ya et al. in 1997.9 In 2013,
Kang group established their synthesis of ()-Kaitocephalin with
the C4 quaternary carbon was installed by the desymmetrization.10
When diol 17 was subjected to benzoylation conditions using the
chiral catalyst 19, the monobenzoate 18 was obtained in 90% yield
with 90% de, which was subsequently converted to the Kaitoceph-
alin diethylamine salt by multi-steps (Scheme 6).
Enzyme catalysis
Leustroducsin B 20 is a mono-tetrahydrofuran acetogenin, iso-
lated by Kohama et al. from the culture broth of Streptomyces plat-
ensis SANK 60191 and shows a variety of biological activities and is
likely to be developed as a new drug candidate.11 In 2003, Fukuy-
ama group reported the ﬁrst total synthesis of Leustroducsin B 20,
in which lipase-mediated enzymatic desymmetrization of the
meso-diol 21 was a key step.12 At ﬁrst, desymmetrization of
meso-diol 21 with Lipase AK and vinyl acetate furnished the opti-
cally active acetate, and then the monoacetate was immediately
protected as its TBS ether 22.13 The optically active 22 was deter-
mined to be 90.2% ee (Scheme 7).
In 2004, Ghosh group employed the enzymatic desymmetriza-
tion of 23 with lipase PS-30 to provide the monoacetate 24 in
99% ee. The monoacetate24 was an effective starting material for
their enantioselective synthesis of important segments that lead
to the total synthesis of ()-Spongidepsin 25.14 Spongidepsin, as
the novel cyclodepsipeptide, displayed potent cytotoxicity against
a variety of cancer cell lines, was isolated from the Vanuatu marine
sponge Spongia sp. by Riccio group15a and was assigned by Forsyth
group (Scheme 8).15b
Murisolin 26 and 16,19-cis-Murisolin 27, which belong to the
murisolin class of monotetrahydrofuran acetogenins, were discov-
ered by Cole group16a in 1982 and shows high cytotoxicity which
rivals that of taxol.16b In 2012, Haufe group developed a novel
Lego-like building block strategy toward the total synthesis of 26
and 27 in 1.6% or 0.2% overall yields.17 In their strategy, desymmet-
rization of inseparable diols 28a, b mixture, gave a 62:38 mixture
of intermediates 29a (96% ee) and 29b (76% ee) by using Candida
rugosa lipase and vinyl acetate (Scheme 9).
Carboxylic esters and anhydrides
In 2001, Trost group18 reported the synthesis of the furanoside
moiety of the C-2 epimer of Hygromycin A 30 which is the ana-
logue of natural product Hygromycin.19 In order to synthesize
the furanoside part of C-2-epi-Hygromycin A 30, they used the
sodium salt of 1-phenylsulfonyl-1-nitroethane 32 to desymmetrize
of bisbenzoate 31. They found that using 4% of ligand 33 with
1%[{N3-C3H5PdCl}2] afforded the monobenzoate 34 in 93% ee. It
should be noted that they chose 32 as an acetyl equivalent becauseOBzO OBz
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Scheme 10. Desymmetrization of bisbenzoate 31.
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ation (Scheme 10).
In 2006, Ojima group developed a highly efﬁcient Pd/phospho-
ramidite ligand-catalyzed asymmetric allylic alkylation. They
employed this method for desymmetrization of meso-1,4-dib-
enzoyloxycyclohex-2-ene 35 to afford 37 with 99.4% ee. From 37,
they only needed ﬁve steps to synthesize the natural product(+)-c-Lycorane 38, which was isolated from the plants of Amaryll-
idacae family and has attracted much attention for its total synthe-
sis (Scheme 11).20
Biotin 39 is one of the water-soluble B vitamins. It was isolated
from egg yolk by Kogl in 1936.21a Later du Vigneaud et al. isolated
it from beef liver and milk concentrates in 1941.21b Although
marked advances in the total synthesis of d-Biotin have been
achieved,21c Chen group developed another new and practical
strategy in 2005.22 One of crucial steps of their approach was
asymmetric enzymatic desymmetrization of meso-dicarboxylic
diester 40. They used immobilized PLE (pig liver esterase) on
Eupergit C as the catalyst and conducted the reaction in buffer
which was kept constant at pH 8. The hemiester 41 was obtained
with 91% ee and the ee value can be upgraded to 98.5% by recrys-
tallization (Scheme 12).
As the marine-derived dimeric pyrrole-imidazole alkaloids,
Sceptrin 42 and Ageliferin 43 have a range of useful bioactivities.23
The racemic form of 42 and 43 has been synthesized by some
groups.24 Baran group reported the ﬁrst asymmetric synthesis of
both enantiomers of Sceptrin 42 and Ageliferin 43 in 2006.25 Their
synthesis commenced with the enzymatic desymmetrization of
meso-diester 44 using PLE in buffer and pH 8 to provide monoester
()-45 in 75% ee. Subsequently, they accomplished the total syn-
thesis of sceptrin 42 and ageliferin 43 with high overall yield
(Scheme 13).
Resolvin E2 46 shows potent anti-inﬂammatory properties in
murine peritonitis.26 Inoue group reported the total synthesis of
Resolvin E2 46 by enantioselective desymmetrization of achiral
meso-anhydride 47.27 With treatment of 47 with 1 mol% of 48 in
methanol, they obtained (+)-49 with 87% ee. Subsequently, the
important fragment synthesized from (+)-49 was assembled into
Resolvin E2 46 easily (Scheme 14).
In 2009, Fukuyama group utilized the desymmetrization of
anhydride 50 to assemble the natural product ()-Huperzine A
52,28 which was isolated from Huperzia serrata by Liu et al. in
1986 and exhibits a potent inhibitory activity against acetylcholin-
esterase.29 Their total synthesis commenced with the desymmetri-
zation of anhydride 50 which was treated with quinine and benzyl
alcohol to give carboxylic acid 51with 93% ee. They obtained a crit-
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zine A 52 (Scheme 15).
Caprazamycin B 53, a novel lipo-nucleoside antibiotic, was iso-
lated from the culture broth of the actinomycete strain Streptomy-
ces sp. MK730-62F2 and shows excellent antimycobacterial
activity in vitro against drug-susceptible and multidrug-resistant
Mycobacterium tuberculosis strains. A simple and convenient syn-
thesis of the western zone of Caprazamycin B using desymmetriza-
tion as one of the key elements was reported by Shibasaki and co-
workers30 In the presence of (S)-Ni2-(Schiff base) 55 complex, 3-
methylglutaric anhydride 54 was treated with BnOH to give the
corresponding chiral hemieste 56 in 87% yield with 88% ee
(Scheme 16).
Very recently, Zhu and co-workers established their synthetic
route of ()-Rhazinilam 57 and ()-Leucomidine 58,31 highlighting
the desymmertrization of bislactone 59 as the key step. Different
kinds of chiral phosphoric acids derived from (S)-BINOL and (S)-
SPINOL were explored in various solvents at 60 C to room tem-
perature. Finally, the optimized conditions were settled down as
that using the catalyst 60 to promote the transformation in 1,4-
dioxane at room temperature, which gave the desired product 61
in 95% yield with 92:8 e.r. (Scheme 17).
a-Carbonyl
Simpkins group developed chiral lithium amide bases (e.g., 64)
catalyzed highly enantioselective desymmetrization of dicarbonylO
O
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Scheme 19. Desymmetrization of meso-diketone 66.derivatives. In 2003, their group32 employed the strategy for asym-
metric total synthesis of medicinal alkaloid (+)-Jamtine 62 which
was reported, in the form of an N-oxide, as one of the small group
of isoquinoline alkaloids isolated from the climbing shrub Cocculus
hirsutus.33 In their route, desymmetrization of meso-imide 63 was
accomplished by employing a monolithiated diamine base 64.
The carboxymethylation product ()-65 was obtained with 98%
ee. Subsequently, they ﬁnished the synthesis of (+)-Jamtine 62 in
4 steps from ()-65 (Scheme 18).
Hirama and co-workers reported desymmetrization of meso-
diketone 66 through an intramolecular aldol reaction in 2003.34
In their desymmetrization protocol, treatment of 66 with
LiN(TMS)2 in THF at 100 C lead to the selective formation of
desired product 67a as the major product. Employing the reaction
as one of key steps, they accomplished the total synthesis of natu-
ral product (±)-Merrilactone A 68, which was isolated from Illicium
merrillianum in 2000, has been shown to possess neurotrophic
activity (Scheme 19).35
Cocaine was isolated from a variety of plant sources (e.g., Hyo-
scyamus niger, Atropa belladonna), has a long and important history
in medicine.36 In 2004, Pearson group utilized intramolecular aldol
reaction to achieve the desymmetrization of meso-dialdehyde 69
for the total synthesis of (+)-Cocaine 71.37 Using the conditions
reported by List, the L-proline catalyzed aldol reaction afforded
products 70 ax/eq as a 1:1 mixture. They synthesized the natural
product (+)-Cocaine 71 in three steps from the 70 ax/eq mixture
(Scheme 20).
In 2005, Renaud group38 developed a radical spirocyclization
approach to a short and efﬁcient synthesis of ()-Erythrodiene
72 which was isolated from Caribbean gorgonian octocoral Ery-
thropodium caribaeorum.39 They utilized desymmetrization of 4-
isopropylcyclohexanone 73 to obtain the key optically pure seg-
ment ()-75. As shown in Scheme 21, deprotonation of 73 with
lithium N,N-bis[(R)-1-phenylethyl]amide (74) and reaction with
methylcyanocarbonate afforded the b-keto ester ()-75 in 94% ee.O
CO2Me
CO2Me
77
OTMS
CO2Me
CO2Me
Ph N
H
Ph
HCl
then TMSCl
79
Yield = 98%
82% ee
78
OMe
N
MeHN
HO
O
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O
HO
HO
HCl
FR90148376
, n-BuLi
Scheme 22. Desymmetrization of prochiral spirofused 77.
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Scheme 23. Desymmetrization of hemiacetal 81.
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Scheme 24. Desymmetrization of 88 via an Schmidt reaction.
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Scheme 25. Desymmetrization of triketone 91.
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alkaloid, was isolated from the fermentation broth of Cladobotryum
sp. and shows biological activity.40 In 2009, Kerr and co-workers
reported the enantioselective total synthesis of FR901483 76.41
The ﬁrst step was desymmetrization of prochiral spirofused 47.
Enol ether 79 was prepared in 82% ee by treating ketone 77 with
the chiral lithium amide derived from 78 in the presence of chloro-
trimethylsilane. Subsequently, FR901483 76 was synthesized
smoothly from 79 (Scheme 22).
Lycoperine A 80, exhibited a moderate inhibitory activity
against acetylcholine esterase from bovine erythrocyte, wasH
N N
Me
N
H
N
Me
H
H
N N
Me
N
H
N
Me
H
H
Allyl acetate
(R,R)-DACT-phenyl
(Trost Ligand)
[(allylPdCl)2]
93 94
Yield = 76%
>99% ee
H
N N
Me
N
H
N
Me
H
H
N
H
N
H
Me
(-)-Hodgkinsine B 95
Scheme 26. Desymmetrization of meso-chimonanthine 93.isolated from the club moss Lycopodium hamiltonii by Kobayashi
and co-workers in 2006.42 Rychnovsky group described the total
synthesis of Lycoperine A 80 through a highly convergent route
which commenced with commercially available diketone 81.43
Diketone 81 was combined with acrolein to afford hemiacetal 82
which was an acyclic version of the underlying symmetric dione.
Desymmetrization of 82 by condensation with amino alcohol aux-
iliaries led to the formation of vinylogous amides 84 in 20:1 dr. The
important segment octahydroquinoline was prepared from 84
straightforwardly (Scheme 23).
The Stemona alkaloids, a class of polycyclic alkaloids, have been
isolated to date from the monocotyledonous family Stemona-
ceae.44 In 2011, Tu and co-workers presented a full account of
the total synthesis of (±)-Maistemonine 85, (±)-Stemonamide 86,
and (±)-Isomaistemonine 87.45 In their route, one of the high-
lighted steps was an intramolecular Schmidt reaction of 88 under
TiCl4 catalyzed conditions, which afforded a desymmetrizing prod-
uct 89 in the form of a single diastereoisomer (Scheme 24).
Cyrneine A 90, featuring a tricyclic 5–6–7 ring system contain-
ing a hexatrienal unit, which enhances neurite outgrowth in pheo-
chromocytoma cells,46 was ﬁrstly total synthesized by Gademann
and co-workers in 2012.47 A remarkable diastereoselective reduc-
tion of the triketone 91 under Luche conditions resulted in high
regioselectivity, and the 5R,6R diastereoisomer 92 was obtained
as the major product in a ratio of 4.25:1, with none of the unlike
diastereoisomers observed. The obtained selectivity could be
explained by the steric hindrance of the substrate and the use of
Luche reagents (Scheme 25).
Amine
In contrast to catalytic asymmetric desymmetrization of meso-
diol, the desymmetrization of diamine was less reported. In
2011, Willis and co-workers reported48 the desymmetrization of
meso-chimonanthine 93 for the total synthesis of natural product
Hodgkinsine B 95 which was isolated from Amazon Psychotria spe-
cies.49 They achieved enantioselective N-monoallylation of meso-
diamine 93 with a (allyl-PdACl)2/Trost ligand catalyst which are
the desymmetrization conditions of Taguchi and co-workers,50 to
afford monoallyl product 94 in >99% ee. This strategy was signiﬁ-
cant for completing their total synthesis (Scheme 26).
Ether
The desymmetrization of diether was less reported too. Liebes-
kind group developed a highly diastereoselective methoxide
abstraction method which relies on the ‘desymmetrization’
imparted by the chiral N-protecting group (CO2R* in 96.51 As
shown in Scheme 27, the 2,6-disubstituted dihydropyridinylmo-
lybdenum complex ()-97a was provided by methoxide abstrac-
tion of ()-96 with Ph3CPF6, subsequent addition of MeMgBr,
then ionization of the other methoxide with HBF4, and addition
of PhMgBr. When reversing the order of nucleophiles addedNMeO OMe
CO2R*
TpMo(CO)2
NR2 R1
CO2R*
TpMo(CO)2
Ph3CPF6 then R1M
HBF4 then R2M
R* = (-)-TCC
96
(-)-97a R1 = Me, R2 = Ph
Yield = 53%
(+)-97b R1 =Ph, R2 = Me
Yield = 62%
N
H
(-)-Dihydropinidine 98
N
H
(-)-Andrachcinidine 99
O
C3H7
OH
Scheme 27. Desymmetrization of diether by methoxide abstraction.
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Scheme 28. Desymmetrization of bicyclic oleﬁn 102.
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Scheme 31. Desymmetrization of divinyl carbinol 111.
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(+)-97b. With the two products in hand, they synthesized the
()-Dihydropinidine 98 and ()-Andrachcinidine 99 (an alkaloid
isolated from Andrachne aspera52) straightforwardly.
The desymmetrization of unsaturated CAC bond
Monoenes
The desymmetrization of unsaturated CAC bonds (including
monoenes and dienes) via hydroxylation or dihydroxylation was
also developed in total synthesis.
Pteridic acid A 100, a spirocyclic polyketide natural product,
having potent plant growth regulator activity, was isolated by Igar-
ashi and co-workers in 2002 from the fermentation broth of Strep-
tomyces hygroscopicus TP-A0451.53a (+)-Bourgeanic acid 101 was
isolated by Bodo et al. in 1973 from the species of lichen Ramali-
na.53b Yadav group utilized the desymmetrization of bicyclic oleﬁn
with Brown’s chiral hydroboration (lpc2BH) to start the total syn-
thesis of natural products 100 and 101.54 As shown in Scheme 28,
hydroxylation of bicyclic oleﬁn 67 with (+)-lpc2BH afforded the
chiral bicyclic alcohol 103 in 97% ee, leading to the total synthesisOPMB
OPMB
OTBS
OPMB
OPMB
OTBS
HO
OH
OPMB
OPMB
OTBS
HO
OH
+
107 108a 108b
108a:108b = 13:1
Sharpless AD
(DHQD)2PHAL
O
O
HO
HO
O
OH
HO
Amphidinolide A 109
Yield = 79%
Scheme 30. Desymmetrization of diene 107.of Pteridic acid A 100. When using the ()-lpc2BH as the catalysis
for the hydroxylation of 102 to afford the enantiomer of 103, they
accomplished the total synthesis of (+)-Bourgeanic acid 101.
Recently, Inoue group described a newly designed route for the
total synthesis of Ryanodol 104,55 a derivative of natural product
Ryanodine, has different biological activities with the other Rya-
noid derivatives.56 The ﬁrst necessitated step of their strategy
was desymmetrization of C2-symmetric intermediate 105. Because
of the strong tendency of the newly generated alcohol to cyclize
into the unreactive hemiacetal, they needed to protect the newly
generated alcohol immediately. Their approach is shown in
Scheme 29, 105was subjected to Et3SiH with 20 mol % of Co(acac)2
and 5 mol % t-BuOOH under an oxygen atmosphere to afford Et3Si-
peroxide 106. This step provided a critical foundation for their total
synthesis of Ryanodol 104 in 22 steps.
Dienes
The desymmetrization of dienes also was involved in the total
synthesis. Trost group described Sharpless AD/(DHQD)2PHAL-cata-
lyzed asymmetric Sharpless dihydroxylation of diene substrate 107
to afford the diols 108a and 108b as a 13:1 mixture with 90% ee.57
Using this strategy, they completed the total synthesis of marine
product Amphidinolide A 109 which was isolated from dinoﬂagel-
late Amphidinium by Kobayashi group in 1986 (Scheme 30).58
Pladienolide B 110was capable of inhibiting the proliferation of
human cancer cells, which was isolated from a Streptomyces platen-
sis (Mer-11107) by Sakai et al. in 2004.59 Ghosh group reported
enantioselective total synthesis of Pladienolide B 110 by employing
asymmetric desymmetrization of commercially available divinyl
carbinol 111 as the ﬁrst step.60 Asymmetric Sharpless epoxidation
of 111 afforded the corresponding epoxide 112 as a single isomer.O
O
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Ph
O
O
MeO Ph
Ph
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MeOH
113 114
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O
O
O
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N OH
O
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Yield = 63%
Scheme 32. Desymmetrization of cyclohexadiene acetal 113.
N N
Ru
MesMes
PhPCy3
Cl
Cl
3 mol%
(S,S,Ps)-119
(S,S)-117
O
PO
O
PO
O
O
O
O O
C6H13
O
O
NHCHO
(-)-Tetrahydrolipstatin 120
Me
OH
Me
OAc
OAc
OAc
Me
OH O Me
nPr
O
OH
Me
OAc
Dolabelide C 121
Yield = 85-90%
118
Scheme 33. Desymmetrization of triene (S,S)-117.
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for the assembly of Pladienolide B 110 (Scheme 31).
(+)-Sch 642305 115 was ﬁrst isolated from Penicillium Verruco-
sum by Chu and co-workers in 2003 and shows to be a potent
inhibitor of bacterial.61 In 2007, Fujioka group developed a concise
asymmetric synthesis of (+)-Sch 642305 115 by chiral auxiliary
multiuse methodology.62a They employed cyclohexadiene acetal
113 as the starting material since the chiral nonracemic hydro-
benzoin in this material can be used as chiral auxiliary for desym-
metrization of itself diene. As shown in Scheme 32, bromo acetal
114 was obtained by intramolecular bromoetheriﬁcation to com-
plete desymmetrization of cyclohexadiene acetal 113. Intermedi-
ate 114 was a critical material for subsequent reaction that led to
the synthesis of (+)-Sch 642305 115. Employing the same method-
ology, they synthesized the natural product Clavolonine 11662b
which was isolated from the clubmoss Lycopodium clavatum by
Burnell and Taylor in 1960.63
()-Tetrahydrolipstatin 120 is an antiobesity drug marketed
and exhibits selective inhibition of thioesterase activity of fatty
acid synthase in cancer cells.64 In 2010, Hanson group reported a
concise total synthesis of ()-Tetrahydrolipstatin 120 in nine steps
from the readily prepared material.65a They synthesized the bicy-
clic phosphate (S,S,PS)-119 via RCM desymmetrization of triene
(S,S)-117 using Grubbs’ catalyst 118. With intermediate (S,S,PS)-
119 in hand, the subsequent steps are unobstructed to complete
the total synthesis of ()-Tetrahydrolipstatin 120. Using the same
desymmetrization strategy, they accomplished the total synthesis
of another natural product Dolabelide C 121,65b which was isolated
from the sea hare Dolabella auricularia in 1997 and exhibited cyto-
toxicity against HeLa-S3 cells (Scheme 33).66
Conclusions
In short, we have summarized the recent developments of
desymmetrization protocol in natural product total synthesis. As
shown in this digest, many efﬁcient desymmetrization strategies
have been employed in total synthesis. With the development of
desymmetrization protocol in organic chemistry, we believe more
and more desymmetrization methods will be applied in total syn-
thesis. In the meanwhile, the exploitation of novel desymmetriza-
tion strategies in total synthesis is necessary as well.
Acknowledgments
Financial support was provided by NBRPC (973 Program,
2015CB856600), NSFC (21472050, 21272075), NCET (120178),
DFMEC (20130076110023), Fok Ying Tung Education Foundation
(141011), the program for Professor of Special Appointment(Eastern Scholar) at Shanghai Institutions of Higher Learning, and
the program for the Changjiang Scholar and Innovative Research
Team in University.
References and notes
1. (a) Hoye, T. R.; Witowski, N. E. J. Am. Chem. Soc. 1992, 114, 7292–7294; (b)
Chen, Y.; McDaid, P.; Deng, L. Chem. Rev. 2003, 103, 2965–2983; (c) Hoffmann,
R. W. Angew. Chem., Int. Ed. 2003, 42, 1096–1109.
2. (a) Hopp, D. C.; Zeng, L.; Gu, Z.-M.; Kozlowski, J. F.; McLaughlin, J. L. J. Nat. Prod.
1997, 60, 581–586; (b) Maezaki, N.; Kojima, N.; Sakamoto, A.; Iwata, C.; Tanaka,
T. Org. Lett. 2001, 3, 429–432; (c) Maezaki, N.; Kojima, N.; Sakamoto, A.;
Tominaga, H.; Iwata, C.; Tanaka, T.; Monden, M.; Damdinsuren, B.; Nakamori, S.
Chem. Eur. J. 2003, 9, 389–399.
3. Zhao, H.; Gorman, J. S. T.; Pagenkopf, B. L. Org. Lett. 2006, 8, 4379–4382.
4. Suzuki, T.; Koizumi, K.; Suzuki, M.; Kurosawa, E. Chem. Lett. 1983, 12, 1639–
1642.
5. Werness, J. B.; Tang, W. Org. Lett. 2011, 13, 3664–3666.
6. West, L. M.; Northcote, P. T.; Battershill, C. N. J. Org. Chem. 2000, 65, 445–449.
7. Trost, B. M.; Michaelis, D. J.; Malhotra, S. Org. Lett. 2013, 15, 5274–5277.
8. (a) Trost, B. M.; Malhotra, S.; Mino, T.; Rajapaksa, N. S. Chem. Eur. J. 2008, 14,
7648–7657; (b) Trost, B. M.; Mino, T. J. Am. Chem. Soc. 2003, 125, 2410–2411.
9. Shin-ya, K.; Kim, J. S.; Furihata, K.; Hayakawa, Y.; Hayakawa, Y.; Seto, H.
Tetrahedron Lett. 1997, 38, 7079–7082.
10. Lee, W.; Youn, J. H.; Kang, S. H. Chem. Commun. 2013, 5231–5233.
11. (a) Kohama, T.; Enokita, R.; Okazaki, T.; Miyaoka, H.; Torikata, A.; Inukai, M.;
Kaneko, I.; Kagasaki, T.; Sakaida, Y.; Satoh, A.; Shiraishi, A. J. Antibiot. 1993, 46,
1503–1511; (b) Kohama, T.; Nakamura, T.; Kinoshita, T.; Kaneko, I.; Shiraishi,
A. J. Antibiot. 1993, 46, 1512–1519; (c) Kohama, T.; Maeda, H.; Imada Sakai, J.;
Shiraishi, A.; Yamashita, K. J. Antibiot. 1996, 49, 91–94.
12. Shimada, K.; Kaburagi, Y.; Fukuyama, T. J. Am. Chem. Soc. 2003, 125, 4048–4049.
13. (a) Akai, S.; Naka, T.; Fujita, T.; Takebe, Y.; Tsujino, T.; Kita, Y. J. Org. Chem. 2002,
67, 411–419; (b) Fadel, A.; Arzel, P. Tetrahedron: Asymmetry 1997, 8, 283–291.
14. Ghosh, A. K.; Xu, X. Org. Lett. 2004, 6, 2055–2058.
15. (a) Grassia, A.; Bruno, I.; Debitus, C.; Marzocco, S.; Pino, A.; Gomez-Paloma, L.;
Riccio, R. Tetrahedron 2001, 57, 6257–6260; (b) Forsyth, C. J.; Chen, J. Angew.
Chem., Int. Ed. 2004, 43, 2148–2152.
16. (a) Jolad, S. D.; Hoffmann, J. J.; Schram, K. H.; Cole, J. R.; Tempesta, M. S.; Kriek,
G. R.; Bates, R. B. J. Org. Chem. 1982, 47, 3151–3153; (b) Nakanishi, Y.; Chang, F.-
R.; Liaw, C.-C.; Wu, Y.-C.; Bastow, K. F.; Lee, K.-H. J. Med. Chem. 2003, 46, 3185–
3188.
17. Persich, P.; Kerschbaumer, J.; Helling, S.; Hildmann, B.; Wibbeling, B.; Haufe, G.
Org. Lett. 2012, 14, 5628–5631.
18. (a) Trost, B. M.; Dirat, O.; Dudash, J., Jr.; Hembre, E. J Angew. Chem., Int. Ed. 2001,
40, 3658–3660; (b) Trost, B. M.; Dudash, J., Jr.; Dirat, O. Chem. Eur. J. 2002, 8,
259–268.
19. Pittenger, R. C.; Wolfe, R. N.; Hohen, M. M.; Marks, P. N.; Daily, W. A.; McGuire,
M. Antibiot. Chemother. 1953, 3, 1268–1278.
20. Chapsal, B. D.; Ojima, I. Org. Lett. 2006, 8, 1395–1398.
21. (a) Kogl, F.; Tonnis, B.; Hoppe-Seyl, Z. Physiol. Chem. 1936, 242, 43–73; (b)
duVigneaud, V.; Hofmann, K.; Melville, D. B.; Gyorgy, P. J. Biol. Chem. 1941, 140,
643–651; (c) De Clercq, P. J. Chem. Rev. 1997, 97, 1755–1792.
22. Chen, F. E.; Chen, X. X.; Dai, H. F.; Kuang, Y. Y.; Xie, B.; Zhao, J. F. Adv. Synth.
Catal. 2005, 347, 549–554.
23. (a) Walker, R. P.; Faulkner, D. J.; Van Engen, D.; Clardy, J. J. Am. Chem. Soc. 1981,
103, 6772–6773; (b) Keifer, P. A.; Schwartz, R. E.; Koker, M. E. S.; Hughes, R. G.,
Jr.; Rittschof, D.; Rinehart, K. L. J. Org. Chem. 1991, 56, 2965–2975.
24. (a) Baran, P. S.; Zografos, A. L.; O’Malley, D. P. J. Am. Chem. Soc. 2004, 126, 3726–
3727; (b) Baran, P. S.; O’Malley, D. P.; Zografos, A. L. Angew. Chem., Int. Ed. 2004,
43, 2674–2677; (c) Birman, V. B.; Jiang, X.-T. Org. Lett. 2004, 6, 2369–2371; (d)
He, Y.; Chen, Y.; Wu, H.; Lovely, C. J. Org. Lett. 2003, 5, 3623–3626; (e)
Kawasaki, I.; Sakaguchi, N.; Fukushima, N.; Fujioka, N.; Nikaido, F.; Yamashita,
M.; Ohta, S. Tetrahedron Lett. 2002, 43, 4377–4380.
25. Baran, P. S.; Li, K.; O’Malley, D. P.; Mitsos, C. Angew. Chem., Int. Ed. 2006, 45,
249–252.
26. Tjonahan, E.; Oh, S. F.; Siegelman, J.; Elangovan, S.; Percarpio, K. B.; Hong, S.;
Arita, M.; Serhan, C. N. Chem. Biol. 2006, 13, 1193–1202.
27. Ogawa, S.; Urabe, D.; Yokokura, Y.; Arai, H.; Arita, M.; Inoue, M. Org. Lett. 2009,
11, 3602–3605.
28. Koshiba, T.; Yokoshima, S.; Fukuyama, T. Org. Lett. 2009, 11, 5354–5356.
29. Liu, J.-S.; Zhu, Y.-L.; Yu, C.-M.; Zhou, Y.-Z.; Han, Y.-Y.; Wu, F.-W.; Qi, B.-F. Can. J.
Chem. 1986, 64, 837–839.
30. Gopinath, P.; Watanabe, T.; Shibasaki, M. J. Org. Chem. 2012, 77, 9260–9267.
31. Gualtierotti, J. B.; Pasche, D.; Wang, Q.; Zhu, J. P. Angew. Chem., Int. Ed. 2014, 53.
http://dx.doi.org/10.1002/anie.201405842.
32. Simpkins, N. S.; Gill, C. D. Org. Lett. 2003, 5, 535–537.
33. Ahmad, V. U.; Rahman, A.; Rasheed, T.; Rehman, H. Heterocycles 1987, 26,
1251–1255.
34. Inoue, M.; Sato, T.; Hirama, M. J. Am. Chem. Soc. 2003, 135, 10772–10773.
35. Huang, J.-M.; Yokoyama, R.; Yang, C.-S.; Fukuyama, Y. Tetrahedron Lett. 2000,
41, 6111–6114.
36. Tufariello, J. J.; Mullen, G. B.; Tegeler, J. J.; Trybulski, E. J.; Wong, S. C.; Ali, S. A. J.
Am. Chem. Soc. 1979, 101, 2435–2442.
37. Mans, D. M.; Pearson, W. H. Org. Lett. 2004, 6, 3305–3308.
M. Wang et al. / Tetrahedron Letters 55 (2014) 7147–7155 715538. Lachia, M.; Dénès, F.; Beauﬁls, F.; Renaud, P. Org. Lett. 2005, 7, 4103–4106.
39. Pathirana, C.; Fenical, W.; Corcoran, E.; Clardy, J. Tetrahedron Lett. 1993, 34,
3371–3372.
40. Sakamoto, K.; Tsujii, E.; Abe, F.; Nakanishi, T.; Yamashita, M.; Shigematsu, N.;
Izumi, S.; Okuhara, M. J. Antibiot. 1996, 49, 37–44.
41. Carson, C. A.; Kerr, M. A. Org. Lett. 2009, 11, 777–779.
42. Hirasawa, Y.; Kobayashi, J.; Morita, H. Org. Lett. 2006, 8, 123–126.
43. Nakamura, Y.; Burke, A. M.; Kotani, S.; Ziller, J. W.; Rychnovsky, S. D. Org. Lett.
2010, 12, 72–75.
44. (a) Pilli, R. A.; de Oliveira, M. C. F. Nat. Pro. Cd. Rep. 2000, 17, 117–127; (b)
Greger, H. Planta Med. 2006, 72, 99–113; (c) Pilli, R. A.; Rosso, G. B.; de Oliveira,
M. C. F. Nat. Prod. Rep. 2010, 27, 1908–1937.
45. Chen, Z. H.; Chen, Z. M.; Zhang, Y. Q.; Tu, Y. Q.; Zhang, F. M. J. Org. Chem 2011,
76, 10173–10186.
46. Marcotullio, C. M.; Pagiotti, R.; Maltese, F.; Obara, Y.; Hoshino, T.; Nakahata, N.;
Curini, M. Planta Med. 2006, 72, 819–823.
47. Elamparuthi, E.; Fellay, C.; Neuburger, M.; Gademann, K. Angew. Chem., Int. Ed.
2012, 51, 4071–4073.
48. Snell, R. H.; Woodward, R. L.; Willis, M. C. Angew. Chem., Int. Ed. 2011, 50, 9116–
9119.
49. Verotta, L.; Peterlongo, F.; Elisabetsky, E.; Amador, T. A.; Nunes, D. S. J.
Chromatogr. A 1999, 841, 165–176.
50. (a) Kitagawa, O.; Yosumoto, K.; Kohriyama, M.; Dobashi, Y.; Taguchi, T. Org.
Lett. 2004, 6, 3605–3607; (b) Kitagawa, O.; Matsuo, S.; Yosumoto, K.; Taguchi,
T. J. Org. Chem. 2006, 71, 2524–2527.
51. Shu, C.; Liebeskind, L. S. J. Am. Chem. Soc. 2003, 125, 2878–2879.
52. Hootele, S. M.; Hootele, C. J. Nat. Prod. 2000, 63, 762–764.
53. (a) Igarashi, Y.; Iida, T.; Yoshida, R.; Furumai, T. J. Antibiot. 2002, 55, 764–767;
(b) Bodo, B.; Hebrard, B.; Molho, L.; Molho, D. Tetrahedron Lett. 1973, 14, 1631–
1634.54. (a) Yadav, J. S.; Rajender, V.; Rao, Y. G. Org. Lett. 2010, 12, 348–350; (b) Yadav, J.
S.; Rao, K. V. R.; Ravindar, K.; Reddy, B. V. S. Eur. J. Org. Chem. 2011, 1, 58–61.
55. Nagatomo, M.; Koshimizu, M.; Masuda, K.; Tabuchi, T.; Urabe, D.; Inoue, M. J.
Am. Chem. Soc. 2014, 136, 5916–5919.
56. (a) Rogers, E. F.; Koniuszy, F. R.; Shavel, J., Jr.; Folkers, K. J. Am. Chem. Soc. 1948,
70, 3086–3088; (b) Sutko, J. L.; Airey, J. A.; Welch, W.; Ruest, L. Pharmacol. Rev.
1997, 49, 53–98.
57. Trost, B. M.; Wrobleski, S. T.; Chisholm, J. D.; Harrington, P. E.; Jung, M. J. Am.
Chem. Soc. 2005, 127, 13589–13597.
58. Kobayashi, J.; Ishibashi, M.; Nakamura, H.; Ohizumi, Y.; Yamasu, T.; Sasaki, T.;
Hirata, Y. Tetrahedron Lett. 1986, 27, 5755–5758.
59. Sakai, T.; Sameshima, T.; Matsufuji, M.; Kawamura, N.; Dobashi, K.; Mizui, Y. J.
Antibiot. 2004, 57, 173–179.
60. Ghosh, A. K.; Anderson, D. D. Org. Lett. 2012, 14, 4730–4733.
61. Chu, M.; Mierzwa, R.; Xu, L.; He, L.; Terracciano, J.; Patel, M.; Gullo, V.; Black, T.;
Zhao, W.; Chan, T.-M.; McPhail, A. T. J. Nat. Prod. 2003, 66, 1527–1530.
62. (a) Fujioka, H.; Ohba, Y.; Nakahara, K.; Takatsuji, M.; Murai, K.; Ito, M.; Kita, Y.
Org. Lett. 2007, 9, 5605–5608; (b) Nakahara, K.; Hirano, K.; Maehata, R.; Kita, Y.;
Fujioka, H. Org. Lett. 2011, 13(8), 2105–2107; (c) Fujioka, H.; Ohba, Y.; Hirose,
H.; Murai, K.; Kita, Y. Angew. Chem., Int. Ed. 2005, 44, 734–737.
63. Burnell, R. H.; Taylor, D. R. Chem. Ind. 1960, 1239–1240.
64. (a) Kridel, S. J.; Axelrod, F.; Rozenkrantz, N.; Smith, J. W. Cancer Res. 2004, 64,
2070–2075; (b) Pemble, C. W.; Johnson, L. C.; Kridel, S. J.; Lowther, W. T. Nat.
Struct. Mol. Biol. 2007, 14, 704–709; (c) Little, J. L.; Wheeler, F. B.; Fels, D. R.;
Koumenis, C.; Kridel, S. J. Cancer Res. 2007, 67, 1262–1269.
65. (a) Venukadasula, P. K. M.; Chegondi, R.; Maitra, S.; Hanson, P. R. Org. Lett. 2010,
12, 1556–1559; (b) Hanson, P. R.; Chegondi, R.; Nguyen, J.; Thomas, C. D.;
Waetzig, J. D.; Whitehead, A. J. Org. Chem. 2011, 76, 4358–4370.
66. Suenaga, K.; Nagoya, T.; Shibata, T.; Kigoshi, H.; Yamada, K. J. Nat. Prod. 1997,
60, 155–157.
